Please login to the form below
Data by
18
Revenue 2014Astellas
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Astellas' 2013 sales performance.
CHMP recommends Teva's generic version of Astellas' Advagraf
CHMP recommends Teva's generic version of Astellas' Advagraf. Committee backs the drug for transplant rejection prophylaxis. ... European regulatory advisors have recommended approval of Teva Pharmaceutical’s generic version of Astellas’transplant
FDA fast-tracks Astellas' Rydapt rival
FDA fast-tracks Astellas' Rydapt rival. AML treatment gilteritinib is currently involved in four phase III trials. ... Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival
Finalists 2017
by Astellas Pharma EMEA. with support from Forster Communications. Merck Growth Hormone eHealth Programme.
Deal Watch May 2017
An example of a big pharma buying a company with a new technology/ product is Astellas which acquired the venture capital owned Belgian company Ogeda for up to $872m. ... Astellas (JP). Company acquisition. Company with NK3 receptor antagonist for hot
Novartis gets EU nod for leukaemia drug Rydapt
The FLT3 inhibitor adds to its US approval in AML
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| Japan revenue 2014 |
|---|
| 1: Takeda |
| 2: Otsuka |
| 3: Meiji |
| 4: Astellas |
| 5: Daiichi Sankyo |
| 6: Teijin |
| 7: Eisai |
| 8: Chugai |
| 9: Mitsubishi Tanabe |
| 10: Kyowa Hakko Kirin |
| 11: Taisho |
| 12: Shionogi |
| 13: Hisamitsu |
| 14: Santen |
| 15: Ono |
| 16: Kyorin |
| 17: Nichi-Iko |
| 18: Mochida |
| 19: Sawai |
| 20: Kaken |
| 21: Kissei |
| 22: Zeria |
| 23: Towa |
| 24: Torii |
| 25: Daito |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
-
Account Director
-
Salary TBC
-
Editorial Director - BioScience
-
Competitive Salary
-
Account Director at PAREXEL MedCom
-
Competitive Salary
- Digital Account Director – Healthcare Communications
-
£50 – 60, 000 benefits
- Scientific Director, Medical Communications
-
£60 – 70, 000 benefits
-
Medical Editor
-
Great salary and benefits
-
Principal Medical Writer
-
Great salary and benefits
- Scientific Team Leader, Medical Education
-
£55, 000 – £70, 000 benefits
- Account Director, Healthcare Communications
-
£50, 000 - £60, 000
Subscribe to our email news alerts
PMHub
Publicis Resolute
Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...
Latest intelligence
- Tools for the digital world
- The next step for the pharma industry...
- How Can We Make Payer Communications Really Sing?
- With so many different influences at play in access decisions, how can we make sure we tap into what’s really driving payer decision-making. How do we go beyond the stated...
- Harnessing the power of core elements to optimise market access
- This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
Quick links
Infographics
